Diabetes patients can reduce their risk of heart failure by 70 per cent

August 9, 2018 by Kristian Sjøgren, ScienceNordic
Diabetes patients can reduce their risk of heart failure by 70 per cent
Diabetes patients can benefit in many ways by following their doctor’s instructions. For example, by reducing their risk of heart failure. Credit: Shutterstock

If patients with type 2 diabetes follow their doctor's advice regarding diet, exercise, quitting smoking, and taking their medication, they can reduce the risk of heart failure by 70 per cent.

This is the conclusion of a new study that has tracked the progress of diabetes patients for 21 years.

Other positive effects previously published include reduced risk of heart attack (myocardial infarction), stroke, amputations of legs and toes, blindness, kidney and nerve damage, and an increased life span of, on average, eight years.

The new results underline the importance of following doctor's instructions.

"These results are the latest addition to a number of results from a research project called The Steno-2 Project, that started in 1993 by the Steno Diabetes Center in Gentofte, Denmark," says project leader Oluf Pedersen, professor, and head of research at the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, Denmark.

"Once again, we show how beneficial an intensive and broad-spectrum intervention is to diabetic patients. Many will in this manner avoid multiple serious disease complications", says Pedersen.

The new study, published in the scientific journal Diabetologia, was conducted by researchers at Slagelse Hospital in Denmark, the University of Southern Denmark, Rigshospitalet in Copenhagen, and the University of Copenhagen.

A warning to follow doctor's advice

The new results could be a hint to diabetes patients who have not been following their doctor's advice, says Troels Krarup Hansen, clinical professor and CEO of the Steno Diabetes Center Aarhus, at Aarhus University Hospital, Denmark.

Hansen was not involved in the new study and describes the project as one of the most influential in terms of diabetes treatment.

"We need these types of studies once in a while to remind both patients and doctors, how important it is to aim for a healthier lifestyle when you have diabetes. You can live many years more with the disease if you do," he says.

Intensive treatment reduces the risk of a wide range of complications by half

The new study is based on data from 160 diagnosed as being at a high risk of developing a wide range of organ damage during the Steno 2 Project in 1993.

At this time, half of the patients were randomly allocated to either a standard treatment group or an intensive treatment group.

The intensive treatment program consisted of more ambitious reductions in blood sugar, cholesterol, and blood clotting, and protein excretion in urine. It also required patients to stop smoking, and for the patient and any spouse to consult with a diet and exercise advisor.

After eight years, both groups were offered the intensive treatment for an additional thirteen years for ethical reasons.

Twenty-one years after the start of the Steno-2 study, twenty-four patients on the standard treatment developed heart failure, while only ten patients in the intensive treatment group developed the condition. That equates to a relative reduced risk of 70 per cent.

Results adopted by international guidelines

Large differences emerged between the two patient groups, just four years in to the project.

Patients in the intensive group had half the risk of developing kidney damage, as well as eye and nerve damage, compared to the control group.

After eight years, patients in the intensive group had half the risk of developing arteriosclerosis.

Results from the Steno-2 project have been adopted by international guidelines for treatment.

Prolonged life expectancy by eight years

Two years ago, the scientists followed up with 93 of the original trial participants who were still alive.

Although all patients had subsequently been offered the intensive treatment program, there were still major differences between the groups.

Most significantly, patients in the original intensive group lived on average, 7.9 years longer than patients in the original control group.

In the original control group, 55 out of 80 people died, compared to 38 out of 80 in the original intensive treatment group.

"We've never seen such a significant extension of life due to an intensive treatment of a chronic disease," says Pedersen.

Explore further: Intensified treatment of patients with type 2 diabetes and known vascular damage extends life by around 8 years

More information: Jens Oellgaard et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study, Diabetologia (2018). DOI: 10.1007/s00125-018-4642-y

Related Stories

Intensified treatment of patients with type 2 diabetes and known vascular damage extends life by around 8 years

September 1, 2016
A long-term Danish follow-up study published in Diabetologia (the journal of the European Association for the Study of Diabetes) now shows that intensified and multifaceted treatment of patients with type 2 diabetes and a ...

Intensive type 2 diabetes treatment can extend survival: study

September 8, 2016
(HealthDay)—Intensive management of type 2 diabetes can make a difference in how long and how well you live, even if you don't start until middle age, researchers report.

Intensive BP goals reduce risk of cardiovascular events

December 19, 2017
(HealthDay)—Intensive blood pressure lowering may similarly decrease cardiovascular events in both patients with and patients without type 2 diabetes mellitus, according to a study published online Dec. 6 in Diabetes Care.

Younger newly-diagnosed patients with type 2 diabetes are hit hard by the disease

December 12, 2017
The common view of type 2 diabetes as an old person's disease is becoming seriously outdated in step with the increasing number of persons under the age of 45 who develop the disease. New research from Aarhus University now ...

Study shows potential cost savings for early detection and treatment of type 2 diabetes

April 17, 2018
Health checks, including diabetes risk assessment, have been introduced in a number of countries. However, there are few population-based trials assessing the benefits, harms and costs of these screening programmes, and these ...

Algorithm identifies hypertensive patients who will benefit from intensive treatment

July 2, 2018
Using data from large clinical trials, UT Southwestern researchers developed a way to predict which patients will benefit most from aggressive high blood pressure treatment.

Recommended for you

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Millions of low-risk people with diabetes may be testing their blood sugar too often

December 10, 2018
For people with Type 2 diabetes, the task of testing their blood sugar with a fingertip prick and a drop of blood on a special strip of paper becomes part of everyday life.

Very low calorie diets trialled by NHS to tackle diabetes

December 7, 2018
Hundreds of thousands of people will receive NHS help to battle obesity and type 2 diabetes under radical action set out by Simon Stevens, Chief Executive of NHS England.

New therapeutic avenue for type 2 diabetes

December 6, 2018
Restoring the action of insulin is one of the keys to fighting type 2 diabetes. Researchers from Inserm led by Dominique Langin at the Institute of Cardiovascular and Metabolic Diseases (Inserm/Université de Toulouse) are ...

Subtype of immune B cells can delay type 1 diabetes onset in mice

December 6, 2018
A team of researchers at Baylor College of Medicine and the University of Michigan Medical School reports today in the JCI Insight that a subset of immune B cells, known as CD19+IgM+ B cells, can delay the onset of type 1 ...

Is the pancreas regeneration debate settled? An original theory renewed

December 5, 2018
A contentious debate among diabetes researchers has surrounded the regeneration of pancreatic insulin-producing cells: not if these cells regenerate, but rather how.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.